论文部分内容阅读
目的分析在体外受精-胚胎移植中应用促性腺激素释放激素拮抗剂超促排卵方案,黄体支持补充雌激素(戊酸雌二醇)对妊娠结局的影响,探讨如何有效运用拮抗剂方案。方法回顾性分析:把进行体外受精-胚胎移植中使用拮抗剂方案的81个新鲜移植周期分为两组:A组黄体支持使用(黄体酮注射剂+戊酸雌二醇)共51例作为研究对象;B组黄体支持使用(黄体酮注射剂)30例作为研究对象。比较两组患者的年龄、优质胚胎率、临床妊娠率等。结果两组年龄、基础促卵泡生成素水平、拮抗剂使用的天数、促性腺激素(Gn)的量、注射绒促性腺激素日雌二醇和黄体生成素水平、获卵数均无明显差别;A组优势胚胎率较B组明显增高(25.63%vs.17.03%),差别有统计学意义(P<0.05);A、B两组临床妊娠率分别为31.4%、40.00%,两者差别无统计学意义。结论促性腺激素释放激素拮抗剂超促排卵方案中黄体支持补充雌激素,对临床结局无提高作用,反而略差。
OBJECTIVE: To analyze the effect of administration of gonadotropin-releasing hormone antagonist superovulation on in vitro fertilization-embryo transfer and the influence of corpus luteum on pregnancy outcome with estrogen replacement therapy (estradiol valerate), and to explore how to effectively use the antagonist. Methods Retrospective analysis: The 81 fresh transplantation cycles using the antagonist in in vitro fertilization-embryo transfer were divided into two groups: A group of luteal support (progesterone injection + estradiol valerate) in total of 51 cases ; Group B corpus luteum support the use of (progesterone injection) 30 cases as the research object. The age, quality embryo rate, clinical pregnancy rate and so on were compared between the two groups. Results There was no significant difference between the two groups in terms of age, basal follicle stimulating hormone level, number of days of antagonist use, amount of gonadotropin (Gn), estradiol and luteinizing hormone injection, and number of oocytes retrieved; A The prevalence of dominant embryo in group A was significantly higher than that in group B (25.63% vs 17.03%, P <0.05). The clinical pregnancy rates in groups A and B were 31.4% and 40.00% respectively, with no statistical difference Significance of learning. Conclusions Gonadotropin-releasing hormone antagonist superoxide ovulation regimen supporting estrogen replacement has no effect on clinical outcome, but slightly worse.